A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 546 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Actual Study Start Date: July 8, 2019
Actual Primary Completion Date: January 24, 2021
Estimated Study Completion Date: May 27, 2024
Arm:
- Experimental: Baricitinib High Dose
- Experimental: Baricitinib Low Dose
- Placebo Comparator: Placebo
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Actual enrolment | 546 |
| Actual Study start date | 08 July 2019 |
| Estimated Study Completion Date | 27 May 2024 |